Particle.news

Stem Cell Grafts Achieve Myelin Repair in Mice, Set Stage for Progressive MS Trial

Following successful animal studies, the RESTORE consortium is poised to launch a first-in-human efficacy trial of induced neural stem cell grafts for progressive multiple sclerosis.

Overview

  • Induced neural stem cells differentiated into mature oligodendrocytes and rebuilt myelin sheaths in chronically demyelinated mouse spinal cords.
  • Human iNSC transplants demonstrated long-term survival and safety in models of central nervous system demyelination without adverse effects.
  • Transplanted mouse iNSCs integrated in Olig1−/− lesions and directly generated new exogenous myelin sheaths in a progressive MS model.
  • The RESTORE consortium is creating a patient-focused trial protocol to assess whether iNSC grafts can remyelinate lesions and restore neurological function in people with progressive MS.
  • Current therapies manage progressive MS symptoms but do not halt or reverse neurodegeneration, highlighting the need for remyelination-based approaches.